Research programme: proto oncogene proteins c-akt inhibitors - Astex/Institute of Cancer Research/Cancer Research Technology

Drug Profile

Research programme: proto oncogene proteins c-akt inhibitors - Astex/Institute of Cancer Research/Cancer Research Technology

Alternative Names: AT 11854; AT 7867; CCT 128930; CCT 129254; CCT077373; CCT077933

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Astex Therapeutics; Cancer Research UK; The Institute of Cancer Research
  • Developer Astex Pharmaceuticals; Cancer Research UK; The Institute of Cancer Research
  • Class Benzamides; Piperidines; Pyrazoles; Pyrimidines; Small molecules
  • Mechanism of Action 70 kDa ribosomal protein S6 kinase inhibitors; Proto oncogene protein c-akt inhibitors; Rho-associated kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in United Kingdom (PO)
  • 11 Oct 2013 Astex Pharmaceuticals has been acquired by Otsuka Pharmaceutical
  • 20 Jul 2011 Astex Therapeutics has been acquired by SuperGen
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top